Prostate Cancer Clinical Trials in Dallas

Showing 101-120 of 237 trials

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT05241613

This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies. The main goals of this study are to: * Identify the recommended dose of AC176 that can be given safely to participants * Evaluate the side effects of AC176 * Evaluate pharmacokinetics of AC176 * Evaluate the effectiveness of AC176

Metastatic Castration Resistant Prostate Cancer

Accutar Biotechnology Inc28 participantsStarted Mar 2022

Denver, Colorado, United States • Sarasota, Florida, United States • Detroit, Michigan, United States +2 more locations

Active Not RecruitingPhase 3< 1 mile

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.

Prostate Cancer

AstraZeneca1,035 participantsStarted Mar 2022

Yuma, Arizona, United States • Beverly Hills, California, United States • Cerritos, California, United States +214 more locations

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Trials in Other Cities

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Comprehensive Outcomes for After Cancer Health

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

Other Conditions in Dallas